Asymmetric hydrogenation provides chiral 2,3-dihydrobenzofurans, suggesting new routes for bioactive applications.
Comprehensive Summary The chiral 2,3‐dihydrobenzofuran (DHB) scaffold is a privileged motif in bioactive natural products and preclinical therapeutic candidates, yet practical enantioselective syntheses remain scarce. We report a chiral Rh/Hf/( S )‐DTBM‐SEGPHOS bimetallic catalytic system enabling asymmetric hydrogenation of benzofurans with hydrogen source, delivering diverse DHBs (37 examples) in excellent yields (up to 98%) and enantioselectivities (up to 99% ee ). Gram‐scale synthesis and deuterium labeling with D 2 O (8 examples) validate the method's scalability and utility in biological studies and drug design.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: